Literature DB >> 6749351

Verapamil in cardiac arrhythmias: an overview.

J Vohra.   

Abstract

1. Verapamil remains the most widely used calcium antagonist for the treatment of cardiac arrhythmias. It is the most potent and effective drug for the acute treatment of paroxysmal supraventricular tachycardia particularly, circus movement tachycardia with or without pre-excitation. 2. As it is a powerful depressant of atrioventricular nodal conduction it reduces the ventricular rate in atrial flutter and fibrillation with reversion to sinus rhythm in a proportion of patients with these arrhythmias. Because verapamil does not increase airways resistance it can be used in patients with obstructive airways disease. The drug is also effective in supraventricular tachyarrhythmias following open-heart surgery and myocardial infarction. 3. It is not an effective drug against ventricular arrhythmias unless due to coronary artery spasm. The use of verapamil should be avoided in the presence of sick sinus node syndrome, clinical cardiac failure and treatment with other negative inotropic drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6749351

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol Suppl        ISSN: 0143-9294


  5 in total

1.  Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells.

Authors:  Lu Zhao; Yue Zhao; Bettina Schwarz; Josef Mysliwietz; Roland Hartig; Peter Camaj; Qi Bao; Karl-Walter Jauch; Makus Guba; Joachim Walter Ellwart; Peter Jon Nelson; Christiane Josephine Bruns
Journal:  Int J Oncol       Date:  2016-05-10       Impact factor: 5.650

2.  Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an RBM20 Patient-Derived iPSC Model.

Authors:  S P Wyles; S C Hrstka; S Reyes; A Terzic; T M Olson; T J Nelson
Journal:  Clin Transl Sci       Date:  2016-04-22       Impact factor: 4.689

3.  Comparative metabonomics of Wenxin Keli and Verapamil reveals differential roles of gluconeogenesis and fatty acid β-oxidation in myocardial injury protection.

Authors:  Miaomiao Jiang; Qiuying Wang; Jingrui Chen; Yanan Wang; Guanwei Fan; Yan Zhu
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

4.  Incorporation of drug efflux inhibitor and chemotherapeutic agent into an inorganic/organic platform for the effective treatment of multidrug resistant breast cancer.

Authors:  Yang Dong; Hongze Liao; Jian Yu; Hao Fu; Ke Gong; Qi Wang; Yourong Duan
Journal:  J Nanobiotechnology       Date:  2019-12-23       Impact factor: 10.435

Review 5.  Progressive Host-Directed Strategies to Potentiate BCG Vaccination Against Tuberculosis.

Authors:  Kriti Negi; Ashima Bhaskar; Ved Prakash Dwivedi
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.